Jefferies Upgrades Regeneron Pharma (REGN) to Buy

U.S. stocks are rising on hopes the Fed is headed for a pause

March 23, 2023 10:31 AM EDT

By Liz Moyer

Investing.com -- U.S. stocks were rising after the Federal Reserve suggested it was nearing the end of its interest rate hikes.

At 10:06 ET (14:06 GMT) the Dow Jones Industrial Average rose 240 points or 0.7%, while the S&P 500 was up 1% and the NASDAQ Composite was up 1.6%.

On Wednesday, the Fed raised rates by the expected quarter of a percentage point, and said in its policy statement that ongoing increases are no longer... More

Raymond James Upgrades Regeneron Pharma (REGN) to Market Perform, 'limited remaining clinical downside catalysts during 2023'

March 23, 2023 10:28 AM EDT

(Updated - March 23, 2023 10:29 AM EDT)

Raymond James analyst Dane Leone upgraded Regeneron Pharma (NASDAQ: REGN) from Underperform to Market Perform.

The analyst comments "Upgrading to Market Perform, as we think there are limited remaining clinical downside catalysts during 2023, but we do... More

Sanofi rises as analysts eye results from smoker's lung drug trial

March 23, 2023 8:20 AM EDT

By Scott Kanowsky

Investing.com -- Shares in Sanofi SA (EPA: SASY) climbed by more than 5%, as analysts noted the "blockbuster potential" of the French drugmaker's asthma and eczema medicine Dupixent after results from a Phase 3 trial showed it met all targets in treating so-called "smoker's lung."

Sanofi said Dupixent, which it developed in conjunction... More

Sanofi (SNY) and Regeneron (REGN) Report Dupixent Met Endpoints in Phase 3 Trial for COPD

March 23, 2023 5:29 AM EDT

Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placeboFirst and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to placebo (77 mL in FEV1)First and only biologic to demonstrate significant improvements in quality of life and respiratory... More

US FDA expands use of Regeneron's cholesterol drug in young children

March 22, 2023 9:44 AM EDT

(Reuters) -Regeneron Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 years to treat an ultra-rare disease that causes high cholesterol.

The drug, Evkeeza, was approved in February 2021 as an additional treatment with other lipid-lowering therapies... More

Regeneron (REGN) Announces FDA Approval of Evkeeza

March 22, 2023 7:02 AM EDT

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for children as young as 5 years old to control dangerously high levels of low-density lipoprotein cholesterol (LDL-C) caused by HoFH. Evkeeza was initially... More

Regeneron (REGN) Announces FDA Approves First-in-class Evkeeza for Young Children with Ultra-rare Form of High Cholesterol

March 22, 2023 7:01 AM EDT

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for children as young as 5 years old to control dangerously high levels of low-density lipoprotein cholesterol (LDL-C) caused by HoFH. Evkeeza was initially... More